Sequential Therapy After Teriparatide for Osteoporosis

Rationale for Sequential Therapy

The American College of Rheumatology recommends starting an antiresorptive medication immediately after completing teriparatide therapy to maintain bone density gains and prevent bone loss, with high strength of evidence 1, 2, 3
Significant bone loss may occur after discontinuation of teriparatide, although anti-fracture efficacy may persist for up to 18 months, with moderate strength of evidence 2, 3
Sequential therapy with an antiresorptive agent is strongly recommended to preserve the bone mass gained during teriparatide treatment, with high strength of evidence 1, 2, 3

The American College of Rheumatology recommends oral bisphosphonates (alendronate, risedronate) as the first choice for sequential therapy after teriparatide due to their efficacy, safety profile, and cost-effectiveness, with high strength of evidence 1, 2, 4
Intravenous bisphosphonates (zoledronic acid) are appropriate alternatives if oral administration is contraindicated or if adherence is a concern, with moderate strength of evidence 1, 2
Denosumab (RANK ligand inhibitor) is an effective second-line option if bisphosphonates are contraindicated, with moderate strength of evidence 4

For patients with low fracture risk after teriparatide, the American College of Rheumatology recommends starting oral bisphosphonate therapy immediately after completing teriparatide, with high strength of evidence 1, 2
For patients who remain at high or very high risk of fracture, consider more potent antiresorptive options such as intravenous bisphosphonates or denosumab, with moderate strength of evidence 1, 2, 3

The optimal duration of sequential therapy is not clearly established, but treatment for at least 1 year with an oral bisphosphonate or 1-2 years with IV bisphosphonate is recommended, with moderate strength of evidence 1, 2
Long-term bisphosphonate therapy should be reassessed after 3-5 years due to potential risks of rare adverse events, with low strength of evidence 4

Bone mineral density testing via DEXA scan should be performed to assess treatment response, with moderate strength of evidence 6
Biochemical markers of bone turnover may be used to assess adherence to antiresorptive therapy, with low strength of evidence 6
Regular assessment of calcium and vitamin D status is recommended, with moderate strength of evidence 4